Burden of HPV related anogenital diseases in young women in Germany - an analysis of German statutory health insurance claims data from 2012 to 2017.
Administrative Claims, Healthcare
/ statistics & numerical data
Adult
Anus Diseases
/ epidemiology
Cohort Studies
Condylomata Acuminata
/ epidemiology
Female
Genital Diseases, Female
/ epidemiology
Germany
/ epidemiology
Humans
Papillomaviridae
/ physiology
Papillomavirus Infections
/ complications
Prevalence
Retrospective Studies
Uterine Cervical Neoplasms
/ epidemiology
Young Adult
Uterine Cervical Dysplasia
/ epidemiology
Cervical intraepithelial neoplasia
Claims data
Genital warts
Germany
Human papillomavirus (HPV)
Prevalence
Statutory health insurance
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
22 Apr 2020
22 Apr 2020
Historique:
received:
30
07
2019
accepted:
29
03
2020
entrez:
24
4
2020
pubmed:
24
4
2020
medline:
26
5
2020
Statut:
epublish
Résumé
Most individuals are infected with human papillomavirus (HPV) at least once in their lifetime. Infections with low-risk types can cause genital warts, whereas high-risk types can cause malignant tumors. The aim of this study was to determine the burden of anogenital diseases potentially related to HPV in young women based on German statutory health insurance claims data. We conducted a retrospective claims data analysis using the "Institute for Applied Health Research Berlin" (InGef) Research Database, containing claims data from approximately 4 million individuals. In the period from 2012 to 2017 all women born in1989-1992, who were continuously insured between the age of 23-25 years were identified. Using ICD-10-GM codes (verified diagnosis in the outpatient sector or primary or secondary diagnosis in the inpatient sector) the administrative prevalence (95% confidence interval) of genital warts (A63.0), anogenital diseases grade I (K62.8, N87.0, N89.0, N90.0), grade II (N87.1, N89.1, N90.1) and grade III (D01.3, D06.-, D06.0, D07.1, D07.2, N87.2, N89.2, N90.2) was calculated (women with diagnosis divided by all women). From 2012 to 2017, a total of 15,358 (birth cohort 1989), 16,027 (birth cohort 1990), 14,748 (birth cohort 1991) and 14,862 (birth cohort 1992) women at the age of 23-25 were identified. A decrease of the administrative prevalence was observed in genital warts (1.30% (1.12-1.49) birth cohort 1989 vs. 0.94% (0.79-1.10) birth cohort 1992) and anogenital diseases grade III (1.09% (0.93-1.26) birth cohort 1989 vs. 0.71% (0.58-0.86) birth cohort 1992). In anogenital diseases grade III, this trend was especially observed for severe cervical dysplasia (N87.2) (0.91% (0.76-1.07) birth cohort 1989 vs. 0.60% (0.48-0.74) birth cohort 1992). In contrast, anogenital diseases grade I (1.41% (1.23-1.61) birth cohort 1989 vs. 1.31% (1.14-1.51) birth cohort 1992) and grade II (0.61% (0.49-0.75) birth cohort 1989 vs. 0.52% (0.42-0.65) birth cohort 1992) remained stable. A decrease of the burden of anogenital disease potentially related to HPV was observed in the younger birth cohorts. This was observed especially for genital warts and anogenital diseases grade III. Further research to investigate this trend for the upcoming years in light of varying HPV vaccination coverage for newer birth cohorts is necessary.
Sections du résumé
BACKGROUND
BACKGROUND
Most individuals are infected with human papillomavirus (HPV) at least once in their lifetime. Infections with low-risk types can cause genital warts, whereas high-risk types can cause malignant tumors. The aim of this study was to determine the burden of anogenital diseases potentially related to HPV in young women based on German statutory health insurance claims data.
METHODS
METHODS
We conducted a retrospective claims data analysis using the "Institute for Applied Health Research Berlin" (InGef) Research Database, containing claims data from approximately 4 million individuals. In the period from 2012 to 2017 all women born in1989-1992, who were continuously insured between the age of 23-25 years were identified. Using ICD-10-GM codes (verified diagnosis in the outpatient sector or primary or secondary diagnosis in the inpatient sector) the administrative prevalence (95% confidence interval) of genital warts (A63.0), anogenital diseases grade I (K62.8, N87.0, N89.0, N90.0), grade II (N87.1, N89.1, N90.1) and grade III (D01.3, D06.-, D06.0, D07.1, D07.2, N87.2, N89.2, N90.2) was calculated (women with diagnosis divided by all women).
RESULTS
RESULTS
From 2012 to 2017, a total of 15,358 (birth cohort 1989), 16,027 (birth cohort 1990), 14,748 (birth cohort 1991) and 14,862 (birth cohort 1992) women at the age of 23-25 were identified. A decrease of the administrative prevalence was observed in genital warts (1.30% (1.12-1.49) birth cohort 1989 vs. 0.94% (0.79-1.10) birth cohort 1992) and anogenital diseases grade III (1.09% (0.93-1.26) birth cohort 1989 vs. 0.71% (0.58-0.86) birth cohort 1992). In anogenital diseases grade III, this trend was especially observed for severe cervical dysplasia (N87.2) (0.91% (0.76-1.07) birth cohort 1989 vs. 0.60% (0.48-0.74) birth cohort 1992). In contrast, anogenital diseases grade I (1.41% (1.23-1.61) birth cohort 1989 vs. 1.31% (1.14-1.51) birth cohort 1992) and grade II (0.61% (0.49-0.75) birth cohort 1989 vs. 0.52% (0.42-0.65) birth cohort 1992) remained stable.
CONCLUSIONS
CONCLUSIONS
A decrease of the burden of anogenital disease potentially related to HPV was observed in the younger birth cohorts. This was observed especially for genital warts and anogenital diseases grade III. Further research to investigate this trend for the upcoming years in light of varying HPV vaccination coverage for newer birth cohorts is necessary.
Identifiants
pubmed: 32321435
doi: 10.1186/s12879-020-05002-w
pii: 10.1186/s12879-020-05002-w
pmc: PMC7178589
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
297Références
Infect Agent Cancer. 2012 Dec 29;7(1):38
pubmed: 23273245
Rev Obstet Gynecol. 2008 Winter;1(1):2-10
pubmed: 18701931
Hum Vaccin Immunother. 2014;10(6):1729-33
pubmed: 24637921
BMC Infect Dis. 2013 Jan 25;13:39
pubmed: 23347441
BMC Infect Dis. 2012 Dec 21;12:367
pubmed: 23259726
Sex Transm Dis. 2013 Jan;40(1):28-31
pubmed: 23250300
BMC Infect Dis. 2017 Aug 14;17(1):564
pubmed: 28806926
Arch Gynecol Obstet. 2015 Mar;291(3):623-9
pubmed: 25138124
BMC Infect Dis. 2013 Mar 13;13:135
pubmed: 23497108
BMC Infect Dis. 2010 Dec 23;10:360
pubmed: 21182757
Dtsch Arztebl Int. 2011 Nov;108(45):771-9; quiz 780
pubmed: 22163258
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2018 Sep;61(9):1170-1186
pubmed: 30167729
BMC Infect Dis. 2017 Nov 9;17(1):714
pubmed: 29121862
J Clin Pathol. 2002 Apr;55(4):244-65
pubmed: 11919208
N Engl J Med. 2015 Feb 19;372(8):711-23
pubmed: 25693011
Pharmacoepidemiol Drug Saf. 2016 Jan;25(1):106-9
pubmed: 26530279
Sex Transm Infect. 2015 May;91(3):214-9
pubmed: 25305210
J Low Genit Tract Dis. 2013 Jul;17(3):289-97
pubmed: 23645067
BMC Infect Dis. 2014 Feb 19;14:87
pubmed: 24552260